[go: up one dir, main page]

CL2008003027A1 - Compuestos derivados de 5,6-diaril piridinas sustituidas en posiciones 2 y 3; compuestos intermediarios y su uso; composicion farmaceutica; y uso para tratar y/o prevenir trastornos psiaquiatricos, metabolicos, inflamatorios, para la prevencion del dolor, entre otras enfermedades. - Google Patents

Compuestos derivados de 5,6-diaril piridinas sustituidas en posiciones 2 y 3; compuestos intermediarios y su uso; composicion farmaceutica; y uso para tratar y/o prevenir trastornos psiaquiatricos, metabolicos, inflamatorios, para la prevencion del dolor, entre otras enfermedades.

Info

Publication number
CL2008003027A1
CL2008003027A1 CL2008003027A CL2008003027A CL2008003027A1 CL 2008003027 A1 CL2008003027 A1 CL 2008003027A1 CL 2008003027 A CL2008003027 A CL 2008003027A CL 2008003027 A CL2008003027 A CL 2008003027A CL 2008003027 A1 CL2008003027 A1 CL 2008003027A1
Authority
CL
Chile
Prior art keywords
prevention
pain
pharmaceutical composition
metabolic
compounds
Prior art date
Application number
CL2008003027A
Other languages
English (en)
Inventor
Christian Congy
Philippe Pointeau
Lionel Barre
Murielle Rinaldi-Carmona
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39387099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003027(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2008003027A1 publication Critical patent/CL2008003027A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos derivados de 5,6-diarilpiridinas sustituidas en posición 2 y 3, compuestos intermediarios, composición farmacéutica, útiles para tratar y/o prevenir trastornos psiquiátricos, trastornos metabólicos, para la prevención del dolor, para la prevención de trastornos gastrointestinales, para el tratamiento y/o la prevención de fenómenos inflamatorios.
CL2008003027A 2007-10-12 2008-10-10 Compuestos derivados de 5,6-diaril piridinas sustituidas en posiciones 2 y 3; compuestos intermediarios y su uso; composicion farmaceutica; y uso para tratar y/o prevenir trastornos psiaquiatricos, metabolicos, inflamatorios, para la prevencion del dolor, entre otras enfermedades. CL2008003027A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0707186A FR2922209B1 (fr) 2007-10-12 2007-10-12 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.

Publications (1)

Publication Number Publication Date
CL2008003027A1 true CL2008003027A1 (es) 2009-10-16

Family

ID=39387099

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003027A CL2008003027A1 (es) 2007-10-12 2008-10-10 Compuestos derivados de 5,6-diaril piridinas sustituidas en posiciones 2 y 3; compuestos intermediarios y su uso; composicion farmaceutica; y uso para tratar y/o prevenir trastornos psiaquiatricos, metabolicos, inflamatorios, para la prevencion del dolor, entre otras enfermedades.

Country Status (20)

Country Link
US (1) US8362045B2 (es)
EP (1) EP2209768A1 (es)
JP (1) JP5465179B2 (es)
KR (1) KR20100065377A (es)
CN (1) CN101855208A (es)
AR (1) AR068778A1 (es)
AU (1) AU2008346293A1 (es)
BR (1) BRPI0818061A2 (es)
CA (1) CA2702012A1 (es)
CL (1) CL2008003027A1 (es)
EA (1) EA201070460A1 (es)
FR (1) FR2922209B1 (es)
IL (1) IL205016A0 (es)
MA (1) MA31839B1 (es)
MX (1) MX2010003983A (es)
PA (1) PA8798201A1 (es)
PE (1) PE20091034A1 (es)
TW (1) TW200922567A (es)
UY (1) UY31387A1 (es)
WO (1) WO2009087285A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103419D0 (es) 2011-02-28 2011-04-13 Univ Aberdeen
WO2013075084A1 (en) * 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013120104A2 (en) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
JP7037507B2 (ja) * 2017-01-26 2022-03-16 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US20030119877A1 (en) 2001-01-02 2003-06-26 Junya Ishida Pyridine derivatives useful as cyclooxygenase inhibitor
AU2003225964B2 (en) * 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
GB0314057D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
FR2876691B1 (fr) * 2004-10-18 2006-12-29 Sanofi Aventis Sa Derives de pyridine, leur preparation, leur application en therapeutique
AU2006236387A1 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl CB1 antagonists

Also Published As

Publication number Publication date
TW200922567A (en) 2009-06-01
JP2011500543A (ja) 2011-01-06
PA8798201A1 (es) 2009-05-15
WO2009087285A4 (fr) 2009-09-24
KR20100065377A (ko) 2010-06-16
EP2209768A1 (fr) 2010-07-28
EA201070460A1 (ru) 2010-10-29
UY31387A1 (es) 2009-05-29
AU2008346293A1 (en) 2009-07-16
MX2010003983A (es) 2010-05-27
JP5465179B2 (ja) 2014-04-09
US8362045B2 (en) 2013-01-29
FR2922209A1 (fr) 2009-04-17
MA31839B1 (fr) 2010-11-01
CA2702012A1 (fr) 2009-07-16
US20100256202A1 (en) 2010-10-07
WO2009087285A1 (fr) 2009-07-16
IL205016A0 (en) 2010-11-30
PE20091034A1 (es) 2009-08-19
BRPI0818061A2 (pt) 2015-03-31
FR2922209B1 (fr) 2010-06-11
CN101855208A (zh) 2010-10-06
AR068778A1 (es) 2009-12-02

Similar Documents

Publication Publication Date Title
CL2008003027A1 (es) Compuestos derivados de 5,6-diaril piridinas sustituidas en posiciones 2 y 3; compuestos intermediarios y su uso; composicion farmaceutica; y uso para tratar y/o prevenir trastornos psiaquiatricos, metabolicos, inflamatorios, para la prevencion del dolor, entre otras enfermedades.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
TW200714604A (en) Substituted heterocycles and the uses thereof
GT200800198A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1.
CL2009000699A1 (es) Compuestos derivados de 6-heteroaril-imidazo[1,2-a]piridinas polisustituidas; composicion farmaceutica; procedimiento de sintesis; compuestos intermediarios; y su uso para tratar o prevenir enfermedades neurodegenerativas, psiquiatricas, inflamatorias, traumatismos cerebrales y de la epilepsia, osteoporosis, cancer, parkinson, entre otras.
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ECSP088804A (es) Antagonistas de los piridil amida de los canales de calcio de tipo t
EA201000365A1 (ru) Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
CL2008003407A1 (es) Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
MY147247A (en) Organic compounds and their uses
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
EA201001865A1 (ru) Противовоспалительные агенты
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.